AstraZeneca and Absci use AI to create cancer drugs
Pharmaceutical company AstraZeneca has signed a deal worth nearly $247 million with Absci, an artificial intelligence company, to develop antibodies to fight cancer, Reuters reports.
Absci's collaboration with AstraZeneca is aimed at…